New type of jab helps to maintain weight loss
New weekly jab targets long-lasting weight loss
- Scientists have developed a new weekly weight loss jab, RES-010, which targets the RNA molecule miR-22, a key regulator of obesity-related processes.
- RES-010 aims to achieve long-lasting weight loss by reprogramming how cells handle fat and energy, boosting mitochondria and converting white fat into brown fat, with initial mouse studies showing promising results.
- A separate study revealed that tirzepatide, marketed as Mounjaro, significantly improved blood sugar control and reduced BMI in young people aged 10 to 17 with type 2 diabetes.
- This research indicated that 79% of young participants on tirzepatide achieved target blood sugar levels after 30 weeks, providing a potential new treatment for youth-onset type 2 diabetes.
- Eli Lilly's new weight loss pill, orforglipron, demonstrated superior blood sugar reduction and greater weight loss compared to oral semaglutide in a head-to-head study involving adults with type 2 diabetes.